Asian Spectator


The Times

.

Guangdong Goods Go Global Promotional Video Released, Extending an Invitation to the World from Guangdong

SHENZHEN, CHINA – Media OutReach Newswire – 18 November 2026 – On November 18–19, the 33rd APEC Economic Leaders' Meeting kicks off in Shenzhen, drawing global attention to Gu...

Etiqa Launches AMBER – A Holistic Retirement Ecosystem That Supports Customers with Their Physical, Mental and Financial Health for Better Quality of Life

SINGAPORE - Media OutReach - 6 May 2021 - Today marks the launch of AMBER by Etiqa("AMBER"), a retirement ecosystem by Etiqa Insurance Singapore. The new platform complements the insurer's g...

Report: BRICS+ likely new counterpoint to G7-led geopolitical order

LOS ANGELES, UNITED STATES - Newsaktuell - 30 April 2024 - The expansion of the BRICS group of nations into what has informally been named BRICS+ could highlight a geopolitical shift, with t...

Young Writers to Share Creative Journeys at Hong Kong Book Fair

Mark O'NeillEnglish Novels Tell Stories about Life and HistoryHONG KONG, Jul 3, 2018 - (ACN Newswire) - The 29th edition of the Hong Kong Book Fair, organised by the HKTDC, will be held 18-...

Swedish Beauty-Tech Brand FOREO Launches AI-Enabled "Beauty Co...

STOCKHOLM, Sept. 4, 2018 /PRNewswire-AsiaNet/-- - AI-Powered Beauty Gadget Makes One Giant Leap for Personalized Skincare Today, Swedish beauty-tech brand, FOREO [http://www.foreo.com ], unv...

Nintex's Global Partner Program Receives 5-Star Recognition fr...

MELBOURNE, Australia, April 3, 2019 /PRNewswire - AsiaNet/ -- CRN's 2019 Partner Program Guide recognises the technology industry's best programs for channel partnersNintex ( https://c212.n...

Poetry as a Cultural Bridge and an Emotional Bond: the 2025 Classical Chinese Poetry Contest Deepens its Cultural Echoes in Southeast Asia

BEIJING, CHINA - Media OutReach Newswire - 29 November 2025 - Heading into its milestone 10th season in 2025, the Classical Chinese Poetry Contest, a cultural phenomenon co-produced by Chi...

ConsenSys Venture Kaleido Invests in APAC in Collaboration wit...

HONG KONG, July 10, 2018 /PRNewswire-AsiaNet/ -- -- To meet surging demand for blockchain solutions among enterprises and governments in APAC, ConsenSys venture Kaleido unveils major investm...

TestingXperts creates history by winning all three major Softw...

MECHANICSBURG, Pa., Nov. 29, 2022 /PRNewswire-AsiaNet/ -- WHEN Manish Gupta [https://www.linkedin.com/in/manish-gupta-94482/] laid the foundation of TestingXperts in 2014, he envisioned it t...

Avance Clinical Wins Frost Sullivan 2020 Asia-Pacific CRO Market Leadership Award

Avance Clinical Wins Frost Sullivan 2020 Asia-Pacific CRO Market Leadership Award

Adelaide, AUS, Jul 9, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. This is the first Frost & Sullivan award for the company which has seen rapid growth in the APAC region over the past year.

Avance Clinical Wins Frost Sullivan 2020 Asia-Pacific CRO Market Leadership Award

Avance Clinical CEO Yvonne Lungershausen

According to Frost & Sullivan:

"The Frost & Sullivan Best Practices Awards have honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry to identify best practices."

Avance Clinical CEO Yvonne Lungershausen:

Commending her team of more than 100 clinical trial specialists throughout Australia and New Zealand, "We have shown, with our repeat business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance Clinical team are very proud.

"Australia, which has successfully managed the COVID-19 crisis, is open for business for clinical trials. This award further reinforces to the biotech community that this is an early phase specialist destination where they can turn around delayed trials. Avance Clinical are experts in facilitating fast study startup with trials typically approved and initiated in under 6 weeks."

Avance Clinical has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years. Avance specialises in supporting biotech companies with their early phase clinical trials, having conducted over 150 early phase (Phase 1 & 2) trials in the past 4 years, involving the treatment of 8,300 participants across 95 therapeutic indications.

According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:

"Within Asia-Pacific's highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. Avance's reputation for high-quality clinical trial outcomes has attracted an impressive 74% repeat business rate, underscoring the company's position as a market leader.

Avance Clinical offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance. The company has grown quickly over the past year doubling staff numbers, with plans to further expand. Avance Clinical offers a real size match for biotechs, meaning better mission understandings and stronger customer service compared to the larger CROs."

In addition to the impressive COVID-19 management in Australia, a key factor in sponsor demand is the speed, access to high-quality sites and attractive cost of running trials in Australia including:- The Australian Government financial rebate of up to 43.5% on clinical trial spend- No IND required for clinical trials and streamlined regulatory processes- Advanced medical, research and scientific community, leading investigators & KOLs, modern medical facilities

Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

Learn about running your next study with Avance Clinical: https://www.avancecro.com/.

About the Frost & Sullivan Awards

The Frost & Sullivan 2020 Best Practices Awards have honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.

With a strong overall performance, Avance Clinical earns the 2020 Asia-Pacific CRO Market Leadership Award. We also recognize that your receipt of this award is the result of many individuals (employees, customers and investors) making daily choices to believe in the organization and contribute in a meaningful way to its future.

About Avance Clinical

Australia's Avance Clinical Pty Ltd has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:1. The Government R&D grant means up to 43.5% rebate on clinical trial spend2. Telehealth pivot during COVID-19 pandemic - speed and continuity3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks4. No IND required for clinical trials5. Full GMP material is not mandated for Phase I clinical trials6. An established clinical trial environment with world-class Investigators and sites 7. Established healthy subject databases and specialised patient populations8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with long track records in FDA compliant research10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round taking advantage of Australia's counter-flu and allergy seasons

Media Contact: media@avancecro.comChris Thompson

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/casino siteleriStreamEastStreamEastjojobetcialis 20 mg fiyat